최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기대한유전성대사질환학회지 = Journal of the Korean Society of Inherited Metabolic Disease, v.16 no.2, 2016년, pp.70 - 78
조성윤 (성균관대학교 의과대학 삼성서울병원 소아청소년과) , 고정민 (서울대학교 어린이병원 소아청소년과) , 이경아 (연세대학교 강남세브란스병원 진단검사의학과)
21-hydroxylase deficiency (21-OHD), most common form of congenial adrenal hyperplasia, is categorized into classical forms, including the salt-wasting (SW) and the simple virilizing (SV) types, and nonclassical (NC) forms based on the severity of the disease. Newborn screening for 21-OHD has been pe...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
신생아 선별검사 무료 검사에는 어떠한 질환이 포함되어 있는가? | 신생아 선별검사가 1985년 국내에 도입된 이후, 2006년부터 국가 지원 하에 시행하는 신생아 선별검사 무료 검사 6개 질환에는 페닐케톤뇨증, 갑상선 기능저 하증, 선천성 부신과형성증, 단풍당뇨증, 호모시스틴뇨증이 있다. 이 중 선천성 부신 과형성증 중 가장 흔한 (95%) 형인 21-hydroxylase deficiency (21-OHD) 는 선별검사에서 21-hydroxylase가 부족할 때 증가 되는 전구체인 17-hydroxyprogesterone (17-OHP) 의 증가로 조기 진단이 가능하다1). | |
21-hydroxylase deficiency의 특징은? | 우리나라에서는 생명의 위협을 주는 염분 소실성 탈수를 예방하고, 여아에서 조기에 바른 성 결정을 하기 위해 모든 신생아에 대해 출생 후 2-4일에 혈액 여과지를 이용하여 17- OHP를 측정하고 있다. 21-OHD는 CYP21A2 유전자의 돌연변이에 의해 발생하며 상염색체 열성으로 유전 된다. 임상 양상은 산전 초음파에서 외부 생식기의 남성화가 발견되는 여아, 소아기에 성조숙증을 보이는 남아(simple virilizing, SV형), 후기 발병으로 고안드로겐 증상을 보이는 경우 (Nonclassical, NC형) 까지 다양하다2-4). | |
21-hydroxylase deficiency 조기 진단이 가능한가? | 신생아 선별검사가 1985년 국내에 도입된 이후, 2006년부터 국가 지원 하에 시행하는 신생아 선별검사 무료 검사 6개 질환에는 페닐케톤뇨증, 갑상선 기능저 하증, 선천성 부신과형성증, 단풍당뇨증, 호모시스틴뇨증이 있다. 이 중 선천성 부신 과형성증 중 가장 흔한 (95%) 형인 21-hydroxylase deficiency (21-OHD) 는 선별검사에서 21-hydroxylase가 부족할 때 증가 되는 전구체인 17-hydroxyprogesterone (17-OHP) 의 증가로 조기 진단이 가능하다1). 우리나라에서는 생명의 위협을 주는 염분 소실성 탈수를 예방하고, 여아에서 조기에 바른 성 결정을 하기 위해 모든 신생아에 대해 출생 후 2-4일에 혈액 여과지를 이용하여 17- OHP를 측정하고 있다. |
White PC. Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol 2009;5:490-8.
Bachega TA, Billerbeck AE, Madureira G, Marcondes JA, Longui CA, Leite MV, et al. Molecular genotyping in Brazilian patients with the classical and nonclassical forms of 21-hydroxylase deficiency. J Clin Endocrinol Metab 1998;83:4416-9.
Paulino LC, Araujo M, Guerra G, Jr., Marini SH, De Mello MP. Mutation distribution and CYP21/C4 locus variability in Brazilian families with the classical form of the 21-hydroxylase deficiency. Acta Paediatr 1999;88:275-83.
Torres N, Mello MP, Germano CM, Elias LL, Moreira AC, Castro M. Phenotype and genotype correlation of the microconversion from the CYP21A1P to the CYP21A2 gene in congenital adrenal hyperplasia. Braz J Med Biol Res 2003;36:1311-8.
Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:4133-60.
Merke DP, Bornstein SR, Avila NA, Chrousos GP. NIH conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Intern Med 2002;136:320-34.
Grosse SD, Van Vliet G. How many deaths can be prevented by newborn screening for congenital adrenal hyperplasia? Horm Res 2007;67:284-91.
Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003;349:776-88.
White PC, Bachega TA. Congenital adrenal hyperplasia due to 21 hydroxylase deficiency: from birth to adulthood. Semin Reprod Med 2012;30:400-9.
New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 1983;57:320-6.
Falhammar H, Wedell A, Nordenstrom A. Biochemical and genetic diagnosis of 21-hydroxylase deficiency. Endocrine 2015;50:306-14.
Concolino P, Mello E, Toscano V, Ameglio F, Zuppi C, Capoluongo E. Multiplex ligation-dependent probe amplification (MLPA) assay for the detection of CYP21A2 gene deletions/duplications in congenital adrenal hyperplasia: first technical report. Clin Chim Acta 2009;402:164-70.
Tajima T, Fujieda K, Nakayama K, Fujii-Kuriyama Y. Molecular analysis of patient and carrier genes with congenital steroid 21-hydroxylase deficiency by using polymerase chain reaction and single strand conformation polymorphism. J Clin Invest 1993;92:2182-90.
New MI, Abraham M, Gonzalez B, Dumic M, Razzaghy- Azar M, Chitayat D, et al. Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc Natl Acad Sci U S A 2013;110:2611-6.
Wilson RC, Mercado AB, Cheng KC, New MI. Steroid 21-hydroxylase deficiency: genotype may not predict phenotype. J Clin Endocrinol Metab 1995;80:2322-9.
Koyama S, Toyoura T, Saisho S, Shimozawa K, Yata J. Genetic analysis of Japanese patients with 21-hydroxylase deficiency: identification of a patient with a new mutation of a homozygous deletion of adenine at codon 246 and patients without demonstrable mutations within the structural gene for CYP21. J Clin Endocrinol Metab 2002;87:2668-73.
White PC, Tusie-Luna MT, New MI, Speiser PW. Mutations in steroid 21-hydroxylase (CYP21). Hum Mutat 1994;3:373-8.
Higashi Y, Tanae A, Inoue H, Fujii-Kuriyama Y. Evidence for frequent gene conversion in the steroid 21-hydroxylase P-450(C21) gene: implications for steroid 21-hydroxylase deficiency. Am J Hum Genet 1988;42:17-25.
White PC, Vitek A, Dupont B, New MI. Characterization of frequent deletions causing steroid 21-hydroxylase deficiency. Proc Natl Acad Sci U S A 1988;85:4436-40.
Morel Y, Andre J, Uring-Lambert B, Hauptmann G, Betuel H, Tossi M, et al. Rearrangements and point mutations of P450c21 genes are distinguished by five restriction endonuclease haplotypes identified by a new probing strategy in 57 families with congenital adrenal hyperplasia. J Clin Invest 1989;83:527-36.
Speiser PW, Dupont J, Zhu D, Serrat J, Buegeleisen M, Tusie-Luna MT, et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992;90:584-95.
Krone N, Arlt W. Genetics of congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009;23:181-92.
Fluck CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley- Bixler syndrome. Nat Genet 2004;36:228-30.
Fukami M, Nishimura G, Homma K, Nagai T, Hanaki K, Uematsu A, et al. Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. J Clin Endocrinol Metab 2009;94:1723-31.
Koyama Y, Homma K, Fukami M, Miwa M, Ikeda K, Ogata T, et al. Two-step biochemical differential diagnosis of classic 21-hydroxylase deficiency and cytochrome P450 oxidoreductase deficiency in Japanese infants by GC-MS measurement of urinary pregnanetriolone/ tetrahydroxycortisone ratio and 11beta-hydroxyandrosterone. Clin Chem 2012;58:741-7.
Jeandron DD, Sahakitrungruang T. A novel homozygous Q334X mutation in the HSD3B2 gene causing classic 3beta-hydroxysteroid dehydrogenase deficiency: an unexpected diagnosis after a positive newborn screen for 21-hydroxylase deficiency. Horm Res Paediatr 2012;77:334-8.
Nordenstrom A, Forest MG, Wedell A. A case of 3beta-hydroxysteroid dehydrogenase type II (HSD3B2) deficiency picked up by neonatal screening for 21- hydroxylase deficiency: difficulties and delay in etiologic diagnosis. Horm Res 2007;68:204-8.
Valentino R, Tommaselli AP, Rossi R, Lombardi G, Varrone S. A pilot study for neonatal screening of congenital adrenal hyperplasia due to 21-hydroxylase and 11-beta-hydroxylase deficiency in Campania region. J Endocrinol Invest 1990;13:221-5.
Cavarzere P, Samara-Boustani D, Flechtner I, Dechaux M, Elie C, Tardy V, et al. Transient hyper-17-hydroxyprogesteronemia: a clinical subgroup of patients diagnosed at neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol 2009;161:285-92.
Silveira EL, Elnecave RH, dos Santos EP, Moura V, Pinto EM, van der Linden Nader I, et al. Molecular analysis of CYP21A2 can optimize the follow-up of positive results in newborn screening for congenital adrenal hyperplasia. Clin Genet 2009;76:503-10.
Coulm B, Coste J, Tardy V, Ecosse E, Roussey M, Morel Y, et al. Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in mainland France between 1996 and 2003. Arch Pediatr Adolesc Med 2012;166:113-20.
Gurian EA, Kinnamon DD, Henry JJ, Waisbren SE. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics 2006;117:1915-21.
Matern D, Tortorelli S, Oglesbee D, Gavrilov D, Rinaldo P. Reduction of the false-positive rate in newborn screening by implementation of MS/MSbased second-tier tests: the Mayo Clinic experience (2004-2007). J Inherit Metab Dis 2007;30:585-92.
Janzen N, Peter M, Sander S, Steuerwald U, Terhardt M, Holtkamp U, et al. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2007;92:2581-9.
Schwarz E, Liu A, Randall H, Haslip C, Keune F, Murray M, et al. Use of steroid profiling by UPLCMS/ MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience. Pediatr Res 2009;66:230-5.
Park S, Kwon A, Yang S, Park E, Choi J, Hwang M, et al. Analysis and cut-off adjustment of dried blood spot 17 alpha-hydroxyprogesterone concentration by birth weight. Journal of The Korean Society of Inherited Metabilic Disease 2014;14:150-5.
Sarafoglou K, Gaviglio A, Hietala A, Frogner G, Banks K, McCann M, et al. Comparison of newborn screening protocols for congenital adrenal hyperplasia in preterm infants. J Pediatr 2014;164:1136-40.
Chennuri VS, Mithbawkar SM, Mokal RA, Desai MP. Serum 17 alpha hydroxyprogesterone in normal full term and preterm vs sick preterm and full term newborns in a tertiary hospital. Indian J Pediatr 2013;80:21-5.
Stanczyk FZ, Clarke NJ. Advantages and challenges of mass spectrometry assays for steroid hormones. J Steroid Biochem Mol Biol 2010;121:491-5.
Speiser PW. Improving neonatal screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 2004;89:3685-6.
Mass Screening C, Japanese Society for Pediatric E, Japanese Society for Mass S, Ishii T, Anzo M, Adachi M, et al. Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision). Clin Pediatr Endocrinol 2015;24:77-105.
Kusuda S, Tachibana K, Saisho S, Yokota I, Igarashi Y, S S. Guideline for treatment of 21-hydroxylase deficiency. J Jpn Pediatr Soc 1999;103:72-5.
Joint LECAHWG. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 2002;87:4048-53.
Bonfig W, Schmidt H, Schwarz HP. Growth patterns in the first three years of life in children with classical congenital adrenal hyperplasia diagnosed by newborn screening and treated with low doses of hydrocortisone. Horm Res Paediatr 2011;75:32-7.
Muthusamy K, Elamin MB, Smushkin G, Murad MH, Lampropulos JF, Elamin KB, et al. Clinical review: Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. J Clin Endocrinol Metab 2010;95:4161-72.
Nimkarn S, Lin-Su K, Berglind N, Wilson RC, New MI. Aldosterone-to-renin ratio as a marker for disease severity in 21-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007;92:137-42.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.